Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hoth Therapeutics, Wise Systems Partner to Leverage AI for Drug Discovery | Contract Pharma
Breaking News

Hoth Therapeutics, Wise Systems Partner to Leverage AI for Drug Discovery

Will leverage the BioNeMo AI platform of Nvidia to build and integrate generative AI applications across the drug discovery pipeline.

Hoth Therapeutics Inc., a patient-focused biopharmaceutical company, has entered into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia. 
 
BioNeMo enables researchers and developers to build and integrate state-of-the-art generative AI applications across the entire drug discovery pipeline—from target identification to lead optimization—with AI workflows. With the help of SRL, Hoth Therapeutics will have the ability to identify, create and leverage its pipeline for additional therapeutics and to further increase value of its assets. 
 
Robert Antofe of Wise Systems International SRL commented, “We’re excited to work with Hoth and leverage our existing AI expertise to help bring further value to both companies through the development of Hoth Therapeutics AI initiatives.”
 
“We believe the Nvidia BioNeMo platform is best in class and with SRL’s assistance we can better grow our IP, leverage our existing pipeline and deliver exciting novel therapeutics to patients in need,” added Robb Knie, Chief Executive Office of Hoth Therapeutics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters